ST. JOSEPH, Mich., June 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the ability to integrate GeneGo’s MetaCore and Agilent Technologies Inc.'s GeneSpring software applications. Users of both will enjoy the interoperability between the two systems as well as the seamless workflow for statistical and functional analysis of gene expression data. Agilent’s GeneSpring is a widely used bioinformatics solution for microarray analysis and data management. MetaCore is the leading functional data mining platform designed for the analysis of different types of experimental data in the context of pathways, networks, cellular processes, diseases and toxic categories.
“With this relationship, we respond to multiple customer requests for integration with GeneSpring,” said Julie Bryant, vice president of Business Development at GeneGo. “GeneGo has an open, market-driven partnering philosophy, and we are happy that Agilent has a similar viewpoint. We look forward to receiving more customer feedback and further developing our systems’ interoperability.”
“The use of informatics to enable life science research has changed dramatically in the last 18 months,” said Jordan Stockton, Agilent Informatics marketing manager. “Today, researchers demand applications that allow them to pool evidence from as many sources as possible. The integration of GeneSpring and MetaCore allows leading scientists to rapidly synthesize information about pathways and molecular interactions with those from microarray technologies.”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 3.2, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at www.genego.com.
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756 7996, julie@genego.com
Web site: http://www.genego.com//
